Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hnin Hnin Khine is active.

Publication


Featured researches published by Hnin Hnin Khine.


Bioorganic & Medicinal Chemistry Letters | 2009

5-Aminomethylbenzimidazoles as potent ITK antagonists

Doris Riether; Renee M. Zindell; Jennifer A. Kowalski; Brian Nicholas Cook; Jörg Bentzien; Stephane De Lombaert; David S. Thomson; Stanley Kugler; Donna Skow; Leslie Martin; Ernest L. Raymond; Hnin Hnin Khine; Kathy O’Shea; Joseph R. Woska; Deborah D. Jeanfavre; Rosemarie Sellati; Kerry L. M. Ralph; Jennifer Ahlberg; Gabriel Labissiere; Mohammed A. Kashem; Steven S. Pullen; Hidenori Takahashi

Benzamide 1 demonstrated good potency as a selective ITK inhibitor, however the amide moiety was found to be hydrolytically labile in vivo, resulting in low oral exposure and the generation of mutagenic aromatic amine metabolites. Replacing the benzamide with a benzylamine linker not only addressed the toxicity issue, but also improved the cellular and functional potency as well as the drug-like properties. SAR studies around the benzylamines and the identification of 10n and 10o as excellent tools for proof-of-concept studies are described.


Bioorganic & Medicinal Chemistry Letters | 2009

Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design

Brian Nicholas Cook; Jörg Bentzien; Andre White; Peter Allen Nemoto; Ji Wang; Chuk Chui Man; Fariba Soleymanzadeh; Hnin Hnin Khine; Mohammed A. Kashem; Stanley Kugler; John P. Wolak; Gregory P. Roth; Stephane De Lombaert; Steven S. Pullen; Hidenori Takahashi

Interleukin-2 inducible T-cell kinase (ITK) is a member of the Tec kinase family and is involved with T-cell activation and proliferation. Due to its critical role in acting as a modulator of T-cells, ITK inhibitors could provide a novel route to anti-inflammatory therapy. This work describes the discovery of ITK inhibitors through structure-based design where high-resolution crystal structural information was used to optimize interactions within the kinase specificity pocket of the enzyme to improve both potency and selectivity.


Bioorganic & Medicinal Chemistry Letters | 2008

Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.

Kevin J. Moriarty; Michael P. Winters; Lei Qiao; Declan Ryan; Renee DesJarlis; Darius Robinson; Brian Nicholas Cook; Mohammed A. Kashem; Paul Kaplita; Lisa H. Liu; Thomas M. Farrell; Hnin Hnin Khine; Josephine King; Steven S. Pullen; Gregory P. Roth; Ronald L. Magolda; Hidenori Takahashi

Previously, we reported a series of novel benzimidazole based Itk inhibitors that exhibited excellent enzymatic potency and selectivity but low microsomal stability. Employing a structure based approach a new series of inhibitors with comparable potency and selectivity to the original series and with a potential for improved microsome stability was identified.


Bioorganic & Medicinal Chemistry Letters | 2008

Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk)

Kevin J. Moriarty; Hidenori Takahashi; Steven S. Pullen; Hnin Hnin Khine; Rosemarie H. Sallati; Ernest L. Raymond; Joseph R. Woska; Deborah D. Jeanfavre; Gregory P. Roth; Michael P. Winters; Lei Qiao; Declan Ryan; Renee DesJarlais; Darius Robinson; Matthew A. Wilson; Mark Bobko; Brian Nicholas Cook; Ho Yin Lo; Peter Allen Nemoto; Mohammed A. Kashem; John P. Wolak; Andre White; Ronald L. Magolda; Bruce Tomczuk

A series of novel potent benzimidazole based inhibitors of interleukin-2 T-cell kinase (Itk) were prepared. In this report, we discuss the structure-activity relationship (SAR), selectivity, and cell-based activity for the series. We also discuss the SAR associated with an X-ray structure of one of the small-molecule inhibitors bound to ITK.


Bioorganic & Medicinal Chemistry Letters | 2008

2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.

Ho Yin Lo; Jörg Bentzien; Roman Wolfgang Fleck; Steven S. Pullen; Hnin Hnin Khine; Joseph R. Woska; Stanley Kugler; Mohammed A. Kashem; Hidenori Takahashi

Based on the information from molecular modeling and X-ray crystal structures, the kinase specificity pocket of ITK could be occupied upon extension of the right-hand-side of the 2-benzimidazole core of the inhibitors. 2-Aminobenzimidazoles with a trans-stilbene-like extension were designed and synthesized as novel ITK antagonists. Significant improvement on binding affinity and cellular activity were obtained through the trans-stilbene-like antagonists. Several compounds showed inhibitory activity in an IL-2 functional assay.


Bioorganic & Medicinal Chemistry Letters | 2008

5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).

Michael P. Winters; Darius Robinson; Hnin Hnin Khine; Steven S. Pullen; Joseph R. Woska; Ernest L. Raymond; Rosemarie Sellati; Charles L. Cywin; Roger J. Snow; Mohammed A. Kashem; John P. Wolak; Josephine King; Paul Kaplita; Lisa H. Liu; Thomas M. Farrell; Renee L. DesJarlais; Gregory P. Roth; Hidenori Takahashi; Kevin J. Moriarty

A series of novel 5-aminomethyl-1H-benzimidazole based inhibitors of Itk were prepared. Structure-activity relationships, selectivity and cell activity are reported for this series. Compound 2, a potent and selective antagonist of Itk, inhibited anti-CD3 antibody induced IL-2 production in vivo in mice.


Bioorganic & Medicinal Chemistry Letters | 2007

Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.

Roger J. Snow; Asitha Abeywardane; Scot Campbell; John Lord; Mohammed A. Kashem; Hnin Hnin Khine; Josephine King; Jennifer A. Kowalski; Steven S. Pullen; Teresa Roma; Gregory P. Roth; Christopher Ronald Sarko; Noel S. Wilson; Michael P. Winters; John P. Wolak; Charles L. Cywin


Tetrahedron Letters | 2008

2-Aminobenzimidazoles as potent ITK antagonists: de novo design of a pyrrole system targeting additional hydrogen bonding interaction

Ho Yin Lo; Jörg Bentzien; Andre White; Chuk Chui Man; Roman Wolfgang Fleck; Steven S. Pullen; Hnin Hnin Khine; Josephine King; Joseph R. Woska; John P. Wolak; Mohammed A. Kashem; Gregory P. Roth; Hidenori Takahashi


Archive | 2009

Drug Discovery Assay for Modulators of HIF-Prolyl Hydroxylase Activity

John Alan Broadwater; Hnin Hnin Khine; Siqi Lin; Richard D. Schneiderman


Bioorganic & Medicinal Chemistry Letters | 2009

Corrigendum to “Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk)” [Bioorg. Med. Chem. Lett. 18 (2008) 5545–5549]

Kevin J. Moriarty; Hidenori Takahashi; Steven S. Pullen; Hnin Hnin Khine; Rosemarie H. Sallati; Ernest L. Raymond; Joseph R. Woska; Deborah D. Jeanfavre; Gregory P. Roth; Michael P. Winters; Lei Qiao; Declan Ryan; Renee DesJarlais; Darius Robinson; Matthew A. Wilson; Mark Bobko; Brian Nicholas Cook; Ho Yin Lo; Peter Allen Nemoto; Mohammed A. Kashem; John P. Wolak; Andre White; Ronald L. Magolda; Bruce Tomczuk

Collaboration


Dive into the Hnin Hnin Khine's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge